NCT03329599View on ClinicalTrials.gov

Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

March 30, 2022

Conditions
AtherosclerosisAdherence, MedicationTolerance
Interventions
DRUG

Polycap

Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule

Trial Locations (1)

Unknown

Kwame Nkrumah University of Science & Technology, Kumasi

All Listed Sponsors
collaborator

Kwame Nkrumah University Teaching Hospital

OTHER

lead

Northern California Institute of Research and Education

OTHER

NCT03329599 - Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment | Biotech Hunter | Biotech Hunter